Navigation Links
GeneNews announces 2007 year end results
Date:3/26/2008

-------

ASSETS

Current

Cash and cash equivalents 11,279,030 20,593,568

Short-term investment 400,000 -

Accounts receivable 1,582,242 135,315

Investment tax credits recoverable 1,038,199 796,900

Prepaid expenses and deposits 512,914 685,819

-------------------------------------------------------------------------

Total current assets 14,812,385 22,211,602

-------------------------------------------------------------------------

Property, plant and equipment, net 3,635,245 1,645,488

Intellectual property, net 400,380 842,528

-------------------------------------------------------------------------

18,848,010 24,699,618

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Accounts payable and accrued liabilities 1,699,153 1,821,355

Deferred revenue 1,204,305 -

Current portion of long-term debt 585,903 102,549

-------------------------------------------------------------------------

Total current liabilities 3,489,361 1,923,904

-------------------------------------------------------------------------

Long-term debt 1,280,916 -

Long-term portion of deferred revenue 401,371 -

-------------------------------------------------------------------------

Total liabilities 5,171,648 1,923,904


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...IRVINE, Calif., Dec. 4 B...FRE), a company focused on changing the world,s tr...of ethanol from non-food cellulosic wastes, has be...of the "50 Hottest Companies in Bioenergy;" the co..., "Having voters rank BlueFire Ethanol among the...
(Date:12/3/2009)...AN FRANCISCO, Dec. 3 VIA...nology company focused on the development of compo...olic disease, today announced that it has complete...inical trial of VIA-2291. ,, The FDG-PET trial...sites in the US and Canada including Massachusetts...
(Date:12/3/2009)...HOPKINTON, Mass., Dec. 3 ...eading provider of tools and services for drug dis...d Living Image 4.0 software for IVIS® in vivo... more than 800 Caliper IVIS systems currently inst...features advanced spectral unmixing tools to enhan...
(Date:12/2/2009)..., NEW YORK, Dec. 2 Reportlinker.... available in its catalogue: ,, Neurostimulati...w.reportlinker.com/p0164232/Neurostimulation---A-G...urostimulation market stands enthused by the growi...e in age-related diseases such as, Parkinson,s, an...
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
...poration (OTC: CGCP), announced that the company w...ptember 30, 2007 prior to market open on,Wednesday...esident Richard,P. Lanigan and Senior Vice Preside...ill host an investor conference call that day at 1... review the company,s financial results and,busine...
...Inc. (CTI) (Nasdaq and MTAX: CTIC) announced precl...EORTC Symposium show its bis-platinate drug,candid...y to currently,marketed platinum agents carboplati...d enter human clinical trials in late 2008. "Bis-...inum-based,chemotherapy drugs with a potential bro...
...Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, N... letter of approval from the U.K. Medicines and He... Clinical Trial Application (CTA) to begin,a clini...YSIN(R) in,combination with cyclophosphamide, a ch...in patients with advanced cancers. The Principal,I...
Other Biology Technology:Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
(Date:12/3/2009)...rctic snowmelt that occurred during the 2008-09 au...ositive phases for two main climate drivers, ENSO ...Hemisphere Annular Mode), according to Dr. Marco T... Sciences at The City College of New York. , P...lty at the CUNY Graduate Center, added that Antarc...
(Date:12/2/2009)...moke their first cigarette within minutes after wa...product of nicotine when processed by the body, th...er of cigarettes smoked. , "Since cotinine le...r results suggest that smokers who smoke immediate... cancer," said researcher Joshua E. Muscat, Ph.D.,...
(Date:12/2/2009)...ut butter, and other foods have done more than rai... They also are quietly fueling a boom in the marke...d safety regulations. That,s the topic of the two-... & Engineering News , (C&EN) ACS, weekly newsmagaz... Senior Correspondent Marc Reisch point out that f...
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 1Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 2Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 3Hospira Reports Second Quarter 2009 Results 53042 1Hospira Reports Second Quarter 2009 Results 53042 2Hospira Reports Second Quarter 2009 Results 53042 3Hospira Reports Second Quarter 2009 Results 53042 4Hospira Reports Second Quarter 2009 Results 53042 5Hospira Reports Second Quarter 2009 Results 53042 6Hospira Reports Second Quarter 2009 Results 53042 7Hospira Reports Second Quarter 2009 Results 53042 8Hospira Reports Second Quarter 2009 Results 53042 9Hospira Reports Second Quarter 2009 Results 53042 10Hospira Reports Second Quarter 2009 Results 53042 11Hospira Reports Second Quarter 2009 Results 53042 12Hospira Reports Second Quarter 2009 Results 53042 13Hospira Reports Second Quarter 2009 Results 53042 14Hospira Reports Second Quarter 2009 Results 53042 15Hospira Reports Second Quarter 2009 Results 53042 16Hospira Reports Second Quarter 2009 Results 53042 17Hospira Reports Second Quarter 2009 Results 53042 18Hospira Reports Second Quarter 2009 Results 53042 19Hospira Reports Second Quarter 2009 Results 53042 20Hospira Reports Second Quarter 2009 Results 53042 21Hospira Reports Second Quarter 2009 Results 53042 22Hospira Reports Second Quarter 2009 Results 53042 23Hospira Reports Second Quarter 2009 Results 53042 24Hospira Reports Second Quarter 2009 Results 53042 25Hospira Reports Second Quarter 2009 Results 53042 26Hospira Reports Second Quarter 2009 Results 53042 27Hospira Reports Second Quarter 2009 Results 53042 28STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York 53040 1
...t endangered cat, the Amur or Far Eastern leopard ... 25 to 34 are left in the wild, renewing fears for...h, World Wildlife Fund along with the Wildlife Con...graphy of the Russian Academy of Science, conducte... , "The recent census confirmed once again that ...
...e an adverse effect on an adult’s performance at w...an also have a negative impact on how well middle ... A study published in the February 15th issue of t... that adolescents who experience sleep disturbance... , James F. Pagel, MD, of the University of Colora...
...y low virus concentration or a sample of water for...ming and difficult process. Researchers at the Geo...have developed an easier and faster method to dete...es using highly porous, micron-sized, silica beads...ultaneously or sequentially add optical and magnet...
Other Biology News:Amur leopard still on the brink of extinction, scientists say 2Sleep disturbances affect classroom performance 2Scientists create dual-modality microbeads to improve identification of disease biomarkers 2Scientists create dual-modality microbeads to improve identification of disease biomarkers 3
8453 UV-Visible Spectrophotometer from Agilent Technologies
... monoclonal [RS17 ] to PRKAR2 cAMP is a signaling...tions. cAMP exerts its effects by activating the c...ces the signal through phosphorylation of differen... is a tetramer composed of two regulatory and two ...
SolidSpec-3700 UV-VIS-NIR Spectrophotometer from Shimadzu
UltraVIEW Upgrade from Andor Technology
Biology Products: